June 15, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ACP has published living clinical guidance to help physicians select medications for patients with overweight or obesity. Unhealthy weight remains a significant public health issue globally, with 68.5% of American adults and 59% of adults worldwide having overweight or obesity, according to Amir Qaseem, MD, PhD, MHA, MGIN, MRCP, FACP, ACP chief science officer and senior vice president of
June 15, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Want obesity drugs covered by insurance? Telehealth companies have a big say

In HelloNation, Medical Weight Loss Expert Patty Schultz Explains Semaglutide and Tirzepatide

Pharmalittle: We're reading about employer coverage of obesity drugs, another Sanofi setback, and more

The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The…

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The…

WASHINGTON — GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists are not likely to…

Once-weekly injectable semaglutide 2.4 mg was linked to reductions in body weight and improvements in multiple cardiometabolic…

Semaglutide combined with counseling 'emerged as the most potent intervention'

A digital weight management program reduced “food noise” for adults with obesity, with greater benefits observed among adults…